Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

Elife. 2020 Jul 10:9:e55513. doi: 10.7554/eLife.55513.

Abstract

Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.

Keywords: aging; cardiac function; diastolic dysfunction; human biology; medicine; mitochondria; mouse; oxidative stress.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / drug effects*
  • Animals
  • Energy Metabolism
  • Female
  • Heart Diseases / drug therapy*
  • Heart Diseases / physiopathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / physiology*
  • Oligopeptides / administration & dosage*
  • Oxidation-Reduction
  • Oxidative Stress*

Substances

  • Oligopeptides
  • arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide